Guerbet
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Guerbet sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Guerbet: 15 sponsored US clinical trials, 1 recruiting.
Guerbet sponsors 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 12 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is CNS Lesion, with 1 trials.
Top-decile sponsor footprint
Guerbet ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640
Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
NCT05590884
Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)
NCT03986138
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
NCT03996447
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
NCT02633501
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
NCT02034708
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
NCT01467271
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
NCT01211873
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
NCT01012674
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
NCT01010932
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)
NCT00980681
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
NCT00845702
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
NCT00793182
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
NCT01092754
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 8 |
| Phase 4 | 4 |
Therapeutic Areas
Where Guerbet enrollment is open (later-stage tilt)
1 recruiting of 15 indexed (7% open); 10 completed (67%).
Phase mix: 12 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: CNS Lesion (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Guerbet: open-pipeline peers nationwide
Peers matched on 15 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Guerbet sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Baylor Breast Care Center · 7% recruiting · 15 trials
- Geron Corporation · 7% recruiting · 15 trials
- Joanne Kurtzberg, MD · 7% recruiting · 15 trials
- Lakefront Biotherapeutics · 7% recruiting · 15 trials
Related
What to do with this Guerbet page
15 registered trials is a research-attention snapshot, not an endorsement of Guerbet or any single study.
- 1 of Guerbet's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- CNS Lesion is the condition Guerbet studies most, compare against other sponsors active in the same condition before evaluating a specific study. See CNS Lesion trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Guerbet pipeline card: 15 registered trials from official public datasets.Report a data error.